Should we all take cholesterol-lowering drugs?
Eat healthy, perform physical activities and ...take your statin. This will perhaps one day the official message of public health to prevent heart attacks, strokes and other cardio-vascular.
In fact, statins are not only for cholesterol treatments. Over the years, these drugs assert themselves more and more as a means of preventing cardio-vascular, including now in people with normal cholesterol levels.
In the U.S., earlier this week, the Federal Drug Agency (FDA) has extended the indications of Crestor, a statin drug marketed by AstraZeneca. This medication may be prescribed to prevent individuals without cardiovascular disease or apparent high LDL cholesterol, but considered at risk for cardiovascular disease.
As evidence of this excess risk, three parameters were selected: age (50 years and more men, 60 women) and the high rate of a marker of cardiac risk, high-sensitivity CRP in the blood and the presence of another risk factor for cardiovascular disease, including hypertension, smoking or family history of heart disease.
These criteria correspond largely to those used in a large study (called Jupiter) published in late 2008, in which Crestor was reduced by 44% the cardio-vascular and 20% mortality compared to placebo. This extension of indication (including other manufacturers of statins could indirectly benefit) is far from anecdotal.
In the United States the population eligible for these treatments could be 16-17 million people, say experts. With a potential profit of several billion for AstraZeneca, maker of Crestor. And the phenomenon could reach Europe in the coming months. AstraZeneca has also filed an application for extension of its statin indications to European Medicines Agency.
The main difference with the United States: the target population would be defined by age and the presence of two vascular risk factors, but not by CRP ultrasensitive. Indeed, the sensitivity CRP is a marker of advanced cardiovascular risk, but it is rarely used in practice.
Do not forget that changes in lifestyle, exercise and diet may also help reduce cardiovascular mortality. And at a lower cost to society.
Recommended articles:
Statins against cholesterol: Still debated
Bisphenol-A: the American drug agency concerned about possible risk
Diabetes: Avandia supervised
Most recent in the category Social Health:
- Usage of Zithromax: A Powerful Antibiotic
- One bed - one habbit
- Be Beneficial by First Aid Training and Courses
- The Advantages of Electric Cigarette Refill
- Researchers managed prevent the aging process in mice
- GPS shoes for Alzheimer patients
- The "standing offices"
- A blood test to know the sex of your child
Last comments
Most read - Social Health
- Italy launches plan to fight against childhood obesity
- Embryonic stem cells: first clinical trials
- Contaminated vegetables: Origin of the deadly bacteria still unknown
- Age: Men often more active than women
- The "standing offices"
- Alcohol can damage sperm
- Proper use iodine tablets
- Cohabitation reduces stress
- The transmission of tuberculosis in planes
- More strokes in winter?
Top rated - Social Health
- Communicate by thought: A hope for patients
- Abu Dhabi gives 25 million dollars for the fight against malaria
- Should we all take cholesterol-lowering drugs?
- The majority of smokers quit without assistance
- Dolphins can help understand human disease
- The transmission of tuberculosis in planes
- Denmark allows heroin under medical supervision
- Five thousand people die of food poisoning each year in the U.S.
- Influenza H1N1 continues to decline
- Age: Men often more active than women
No comments. Be the first to comment the article!